

February 26, 2020

# DRUG DISCOVERY & DEVELOPMENT



| Date  | Time                      | Track  | Presentation Title   | Speaker  |
|-------|---------------------------|--|--|--|
| 1-Jan | 06:00<br>-<br>07:00<br>AM | New Practices<br>in Early Phase<br>Drug<br>Discovery   | 3D-Micro Tissues in Translational Toxicology<br>and Disease Modelling                    | Armin Wolf, PhD<br>Chief Scientific Officer, InSphero AG   |
| 1-Jan | 06:00<br>-<br>07:00<br>AM | Advancement<br>of Biomarkers<br>in Drug<br>Development | CK18 as a Biomarker in NASH Clinical Trials  | Jessica Tuohy, PhD<br>Scientific Product Manager, DiaPharma Group, Inc.  |
| 1-Jan | 06:00<br>-<br>07:00<br>AM | New Practices<br>in Early Phase<br>Drug<br>Discovery   | Generation of expanded primary liver cells   | Astrid Nörenberg, PhD<br>Managing Director, upcyte technologies GmbH   |
| 1-Jan | 06:00<br>-<br>07:00<br>AM | New Practices<br>in Early Phase<br>Drug<br>Discovery   | Human Tissue models for better therapies   | Sebastiaan Trietsch, PhD<br>Chief Technology Officer, Mimetas -The Organ on a Chip Company                     |
| 1-Jan | 06:00<br>-<br>07:00<br>AM | Advancement<br>of Biomarkers<br>in Drug<br>Development | Measuring What Matters: Proliferation and<br>Cell Death Biomarkers for Oncology Research | Olivia Stricker, PhD<br>Commercial Business Development Manager, Diapharma Group, Inc.                         |
| 1-Jan | 06:00<br>-<br>07:00<br>AM | New Practices<br>in Early Phase<br>Drug<br>Discovery   | Microfabricated Human Liver Tissues for Drug<br>Development                              | Salman Khetani, PhD<br>Associate Professor, Department of Bioengineering, University of Illinois<br>at Chicago |
| 1-Jan | 06:00<br>-<br>07:00<br>AM | New Practices<br>in Early Phase<br>Drug<br>Discovery   | Microphysiological Systems for Human<br>Focused Drug Discovery                           | Tomasz Kostrzewski, PhD<br>Director, Biology, CN Bio Innovations Limited                                       |

|        |                           |  |   |   |
|--------|---------------------------|--|---|---|
| 1-Jan  | 06:00<br>-<br>07:00<br>AM | New Practices<br>in Early Phase<br>Drug<br>Discovery   | Organoids: A Revolutionary New Tool for Drug<br>Screening   | Rekha Pal, PhD<br>Director, Scientific Engagement, Crown Bioscience, Inc.   |
| 1-Jan  | 06:00<br>-<br>07:00<br>AM | Modern<br>Approaches to<br>Clinical<br>Development     | Uncovering the mechanism of stress-resistant<br>DNA replication in cancer cells using a<br>modern single-molecule technique                                   | Chames Kermi, PhD, PharmD<br>Postdoctoral Fellow, Chemical and Systems Biology, Stanford University<br>School of Medicine   |
| 1-Jan  | 06:00<br>-<br>07:00<br>AM | New Practices<br>in Early Phase<br>Drug<br>Discovery   | Using 3D cell culture models and high content<br>confocal imaging to evaluate efficacy and<br>expose toxic liabilities in the drug<br>development pipeline    | Erin Edwards, PhD<br>Head of Services, Visikol, Inc.  |
| 1-Jan  | 06:00<br>-<br>07:00<br>AM | Advancement<br>of Biomarkers<br>in Drug<br>Development | Vancomycin: How might Urinary Biomarkers<br>and Precision Dosing create Precision<br>Medicine for the most frequently utilized<br>antibiotic in the hospital? | Marc H. Scheetz, PharmD, MSc, FCCP, FCP<br>Associate Dean of Research and Professor, College of Pharmacy,<br>Professor, College of Graduate Studies, Departments of Pharmacology<br>and Biomedical Sciences, Director, Pharmacometrics Center of<br>Excellence, Midwestern University |
| 26-Feb | 06:00<br>-<br>07:00<br>AM | Modern<br>Approaches to<br>Clinical<br>Development     | Keynote Presentation: Discovery and<br>Development of a Novel First-in-Class<br>Resuscitative Agent   | Professor Anil Gulati, MD, PhD<br>Chairman & Chief Executive Officer of Pharmazz, Inc.; Adjunct Professor,<br>Colleges of Pharmacy and Graduate Studies, Midwestern University;<br>Department of Bioengineering, University of Illinois   |
| 26-Feb | 07:30<br>-<br>08:30<br>AM | Modern<br>Approaches to<br>Clinical<br>Development     | Keynote Presentation: Emerging Drug<br>Combinations: Evolution From Pre-Clinical<br>Discovery to Clinical Development   | Khyati Shah, PhD<br>Post Doctoral Research Scholar at University of California, San Francisco   |
| 26-Feb | 09:00<br>-<br>10:00<br>AM | Modern<br>Approaches to<br>Clinical<br>Development     | CRISPR Based Screening: Advantages of<br>Transcriptional Activators and Inhibitors  | Andrew Ravanelli, PhD<br>Senior R&D Scientist, Genome and Epigenome Editing, MilliporeSigma   |
| 26-Feb | 10:30<br>-<br>11:30<br>AM | Modern<br>Approaches to<br>Clinical<br>Development     | QIAGEN CLC Genomics Workbench 20 -<br>scalable software for NGS data analysis   | Leif Schauer, PhD<br>Director, Global Product Management, QIAGEN  |
| 26-Feb | 12:00<br>-<br>01:00<br>PM | New Practices<br>in Early Phase<br>Drug<br>Discovery   | Characterizing the role of B cells in Response<br>to Immunotherapy with the NanoString GeoMx<br>Platform  | Sarah Warren, PhD<br>Senior Director of Advanced Applications, NanoString Technologies  |

|        |                           |  |  |  |
|--------|---------------------------|--|--|--|
| 26-Feb | 01:30<br>-<br>02:30<br>PM | New Practices<br>in Early Phase<br>Drug<br>Discovery | Automated cell separation for drug discovery<br>assays | Josh Mahlios, PhD<br>Senior Marketing Product Manager, Miltenyi Biotec |
|--------|---------------------------|--|--|--|